Result of 2024 Annual General Meeting
Wednesday June 12, 2024
Wednesday June 12, 2024
Destiny Pharma plc
(“Destiny Pharma” or “the Company”)
Result of Annual General Meeting
Brighton, United Kingdom ‐ 12 June 2024 ‐ Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life‐threatening infections, announces that all resolutions proposed to shareholders at the Annual General Meeting held earlier today were duly passed.
The full text of each resolution was included in the notice of the meeting which was made available on the Company’s website and posted to shareholders on 9 May 2024. The results for the resolutions will shortly be available on the Investors’ section of the Company’s website, destinypharma.com.
For further information, please contact:
Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
FTI Consulting
Ben Atwell / Simon Conway / Michael Trace
+44 (0) 203 727 1000
destinypharma@fticonsulting.com
Shore Capital (Nominated Adviser and Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
About Destiny Pharma
Destiny Pharma is an innovative, clinical‐stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life‐threatening infections. The company’s drug development pipeline includes two late‐stage assets: XF‐73 nasal gel, a proprietary drug targeting the prevention of post‐surgical staphylococcal hospital infections including MRSA, a microbiome‐based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US.